A drug combination that shows little overall survival benefit in white men with advanced prostate cancer has a far greater effect in Black men with the disease, according to interim results from a study led by the Duke Cancer Institute. Nate Saunders talked with Dr. Daniel George, professor in the departments of Medicine and Surgery at Duke University School of Medicine.